nab-sirolimus (ABI-009) Pipeline Clinical Studies

  • Aadi’s phase 2 registrational trial for nab-sirolimus (ABI-009) in patients with advanced PEComa (perivascular epithelioid cell tumors) has been completed
  • nab-sirolimus (ABI-009) has received FDA and EMA Orphan Designation for PEComa as well as FDA Fast Track and Breakthrough Therapy designation for advanced (metastatic or locally advanced) malignant PEComa
  • Aadi is also a recipient of FDA’s Orphan Product Development Grant for this indication